We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Sionex Continues to Strengthen its Patent Portfolio

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Sionex Continues to Strengthen its Patent Portfolio"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Sionex Corporation has announced that the US Patent Office has issued a further seven patents to add to its existing portfolio.

The newly issued US patents;

7,119,328 B2: System for DMS peak resolution.

7,098,449: Spectrometer chip assembly.

7,091,481 B2: Method and apparatus for plasma generation.

7,075,068 B2: Method and apparatus for electrospray augmented high field asymmetric ion mobility spectrometer.

7,045,776 B2: System for collection of data and identification of unknown ion species.

7,030,372: Micromachined field asymmetric ion mobility filter and detection.

7,057,168: Systems for differential mobility analysis.

These newly issued patents add to Sionex’s core IP for the microDMx™ technology and further extend its applicability for a wide range of analysis, monitoring and detection scenarios.

The microDMx technology allows the detection of chemical compounds down to parts per trillion (ppt) levels with a degree of specificity unmatched by any other current technology.

"Sionex is continually strengthening our patent portfolio as a key strategy," said Raanan Miller, Sionex’s founder and chief technology officer.

"Part of that strategy is to foster and develop key relationships and collaborations with world-class research institutes and academia."

"We still have an extremely close relationship with The Charles Stark Draper Laboratory in Cambridge, MA, for developments and improvements to our technology."